Skip to content
Dosage GuideResearch Reference

Pemvidutide Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for Pemvidutide. All information is for educational purposes only.

Quick Answer

In clinical trials, pemvidutide is administered once weekly via subcutaneous injection. The Phase 2 MOMENTUM trial evaluated doses ranging from 1.2 mg to 2.4 mg. Dose adjustments should be made under the guidance of a healthcare professional.

→ Pemvidutide Benefits→ Pemvidutide Side Effects→ Full Pemvidutide Profile
Table of Contents

Standard Dosage Range

Research dosing range: 1.2 mg – 2.4 mg once weekly

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Weight Loss

1.2–2.4 mgOnce weekly
Duration

Ongoing, titrate based on tolerance and efficacy

Subcutaneous injection. Start at a lower dose and titrate upwards to the target dose, guided by a healthcare provider. Doses above 2.4mg have not been extensively studied.

MASLD/MASH (Metabolic Dysfunction-Associated Steatohepatitis)

1.2–2.4 mgOnce weekly
Duration

Ongoing, titrate based on tolerance and efficacy

Subcutaneous injection. Clinical trials suggest significant liver fat reduction at these dosages. Monitor liver enzymes and adjust dose accordingly.

Type 2 Diabetes Management

1.2–2.4 mgOnce weekly
Duration

Ongoing, titrate based on tolerance and efficacy

Subcutaneous injection. Consider potential synergistic effects with other diabetes medications. Monitor blood glucose levels closely.

Timing & Frequency

Pemvidutide is administered once weekly at any time of day, though consistency in timing each week may improve adherence. It can be administered with or without food.

Cycle Guidance

Pemvidutide is generally used for chronic conditions like obesity and MASLD/MASH and is not typically cycled. Discontinuation should be discussed with a healthcare provider.

Reconstitution Reference

Quick reference for reconstituting Pemvidutide. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeSingle-dose prefilled pen
BAC Water VolumeN/A
Concentration & DrawN/A
StorageStore refrigerated at 2–8°C until use. Protect from light.
StabilityRefer to the manufacturer’s instructions for storage and stability information for the prefilled pen.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the typical starting dosage for pemvidutide?
Clinical trials have initiated treatment with dosages around 1.2 mg once weekly, with subsequent titration based on individual tolerance and response.
How long does it take to see results from pemvidutide?
Clinical trials have demonstrated significant weight loss and liver fat reduction within 12-48 weeks of treatment, although individual responses may vary.
Can I take pemvidutide if I have kidney problems?
Consult with your healthcare provider if you have any kidney issues, as dose adjustments may be necessary. Pemvidutide has not been extensively studied in individuals with severe renal impairment.
Can pemvidutide be used in children?
Pemvidutide is not indicated for use in pediatric populations. Its safety and efficacy have not been established in individuals under 18 years of age.

Last updated: 2026-02-19